Multimodal Early Detection of Anthracycline-Induced Cardiotoxicity Using Layer-Specific Strain Analysis

Multimodal Early Detection of Anthracycline-Induced Cardiotoxicity Using Layer-Specific Strain Analysis - CARDIAC-STRAIN

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039155

Enrollment

120

Registered

2026-01-29

Start date

2025-11-25

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I42.7

Interventions

Group 1: Patients scheduled for anthracycline-based chemotherapy undergo serial cardiac imaging at 4 timepoints: baseline, after cycle 4, 4 weeks post-chemotherapy, and 6 months post-treatment. Each a

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Planned anthracycline-based chemotherapy; written informed consent; adequate image quality for echocardiography

Exclusion criteria

Exclusion criteria: Pre-existing cardiomyopathy (LVEF <50%); contraindications for cardiac MRI (pacemaker, severe claustrophobia, GFR <30 ml/min); prior anthracycline therapy; pregnancy

Design outcomes

Primary

Measure	Time frame
WHAT: Change in subendocardial longitudinal strain. WHEN: 6 months post-treatment compared to baseline. HOW: Speckle tracking echocardiography (Medis Suite QStrain software)	—

Secondary

Measure	Time frame
Changes in GLS, LVEF, T1/T2 mapping values and ECV; correlation between strain parameters and MRI tissue characterization; incidence of clinically manifest cardiotoxicity.	—

Countries

Germany

Contacts

Public ContactNino Kavelashvili

Marienhospital Gelsenkirchen

n.kavelashvili@st-augustinus.eu020917253654

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026